Takeda Pharmaceuticals International GmbH grew into a top 10 pharmaceutical company for the first time in 2019 in a sign of how drug developers often rely on M&A to fuel game-changing growth. The company ranked as the number nine pharmaceutical player in the world in the Scrip 100 rankings, based on 2019 pharmaceutical revenues of $30.19bn, moving up substantially in the rankings from number 16 in 2018 and number 18 in 2017.
It was the acquisition of the rare disease specialist Shire that powered Takeda into the top 10. The change represents...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?